No results found

Check the spelling or try searching for a more general term.

ESCRS 2019

ESCRS 2019

Ellex® invites you to join us in Paris for the 2019 meeting of the European Society of Cataract and Refractive Surgeons (ESCRS), 14-18 September. Transforming outcomes and quality of life for patients with glaucoma will be a highlight at ESCRS 2019 – and Ellex® is at the forefront of efforts to help shift the treatment paradigm towards the proactive care of
glaucoma patients. Our leading edge technologies, such as iTrack™ canal-based glaucoma surgery, give ophthalmologists the ability to treat glaucoma across the full spectrum of the disease and enables significant numbers of patients to minimize or obviate the need for medications to control their glaucoma.

“The next step in canal­‐based glaucoma surgery”


Performed as a stand‐alone procedure or as an adjunct to cataract surgery, iTrack™ canal‐based glaucoma surgery flushes out the natural outflow channels, without damaging tissue, and without leaving behind a stent or shunt. Designed to re-­establish the eye’s natural outflow drainage system, this atraumatic, ab-­interno procedure accesses, catheterizes, and viscodilates the trabecular meshwork, Schlemm’s canal, and also the distal outflow system, beginning with the collector channels. As an added benefit, iTrack™ canal‐based glaucoma surgery can be used in conjunction with MIGS devices or treatments — and, as an angle‐sparring procedure, it does not preclude future treatment options.

  • Restores the natural outflow pathway —safely and efficaciously
  • Addresses all outflow pathway resistance points
  • Comprehensively addresses blockages in the collector channel ostia
  • Can be performed in conjunction with cataract surgery, and as a standalone procedure
  • Can be performed across the entire glaucoma disease process — before, and after, MIGS
  • Delivers 30% reduction in mean IOP and a 50% reduction in medication dependence

MEET THE EXPERT SESSIONS, iTRACK™

ELLEX® EXHIBIT #C108

Stop by the Ellex® Exhibit #C108 to meet MIGS experts Dr. Fiamma Campana and Dr. David Lubeck to discuss their treatment pearls and surgical tips for iTrack™ canal-based glaucoma surgery.

FACULTY

Fiamma Campana
MD (USA)
David Lubeck
MD (USA)

SATURDAY, 14 SEP
3:00pm - 4:00pm

SUNDAY, 15 SEP
3:00pm - 4:00pm

REGISTER YOUR INTEREST

Note: this session is not part of the official program of the ESCRS 2019.

MIGS SKILLS TRANSFER COURSE

“Modern MIGS Techniques Not Using Implants”

Join Dr. Zaid Khoueir, Dr. Inder P. Singh andProf. Maya Mϋller for a hands-on skills transfer lab featuring a range of stent‐free, ab‐interno MIGS options, including iTrack™ canal‐based glaucoma surgery. Two course options are available. Registration is available via the ESCRS 2019 website.

COURSE DIRECTOR:

Ziad Khoueir, MD

FACULTY

Inder P. Singh
MD (USA)
Maya Mϋller
MD, PhD (Italy)

COURSE 37:
Monday, 16 September
1:00pm – 4:00pm
Room:
2

COURSE 38:
Monday, 16 September
4:30pm – 7:30pm
Room:
2

Note: this session is hosted as part of the official program of the ESCRS 2019.

SCHLEMM'S CANAL SURGERY COURSE

IC47 Schlemm’s Canal Surgery Course (Ab-Interno and Ab-Externo)

Canaloplasty pioneer Prof. Robert Stegmann will be joined by a leading faculty of glaucoma experts, including Prof. Maya Mϋller and Dr. Clive Peckar to host a comprehensive course addressing the latest developments in canal‐based surgical techniques. Registration is available via the ESCRS 2019 website.

FACULTY

Maya Mϋller
MD, PhD (Italy)
Clive Peckar
MD (UK)
Robert Stegmann
PhD, MD (South Africa)

DATE:
Monday, 16 September

Note: this session is hosted as part of the official program of the ESCRS 2019.

“While various MIGS devices may work on specific sections of the outflow system, the multiple mechanisms of iTrack™ let us hedge our bets and, in my opinion, have a better chance of getting that reduction of pressure in the right type of patient population.”

INDER PAUL SINGH, MD
EYE CENTERS OF RACINE AND KENOSHA, WISCONSIN, USA

“The preferred first-­line therapy for glaucoma”


For nearly 20 years, SLT has played a fundamental role in the treatment of glaucoma and ocular hypertension. Proven to be as effective as medication, both as first-­line treatment and as adjunctive treatment, SLT also alleviates the burden of patient non-compliance and detrimental effect on patient quality of life. It also pairs seamlessly with MIGS procedures.

The randomized multi‐center LiGHT trial has recently shown SLT to be the preferred first‐line treatment for patients with glaucoma or ocular hypertension.

  • SLT is a therapy and not a surgical treatment – it is gentle, does not destroy tissue, and can be repeated. 
  • SLT can lower IOP as effectively as medication
  • SLT is a highly effective first­‐line therapy, and is particularly well suited to patients who are known to be noncompliant with medication 
  • SLT can be used as a replacement treatment if medication is not well tolerated
  • SLT is a highly effective adjunct treatment in combination with medications
  • SLT is not argon laser trabeculoplasty (ALT), which causes permanent damage to the structure of the TM

MEET THE EXPERT SESSIONS, SLT

ELLEX® EXHIBIT #C108

Visit Ellex® during ESCRS 2019 to discover how SLT with the Ellex® Tango™ portfolio of laser systems can help you provide the best care for your glaucoma patients.

SATURDAY, 14 SEP
3:00pm – 4:00pm

SUNDAY, 15 SEP
3:00pm – 4:00pm

Register your interest

Note: this session is not hosted as part of the official program of the ESCRS 2019.

"The safety profile of SLT is so great, I would argue that it's actually a safer first option than many of the medications."

DAVID RICHARDSON, MD (USA)

“Visualize. Vaporize. Focus on improving patient quality of life.”


Proven to be safe and effective, Ellex® Reflex™ Technology for Laser Floater Treatment can provide much-­needed relief from eye floaters and significantly improve a patient's perception of their everyday visual functionality.

Once considered a benign part of the aging process, an increasing number of patients are complaining of floaters and the debilitating impact they have on their quality of life.

With Reflex Technology, the industry’s only laser platform designed specifically for laser­‐based floater treatment, you are now able to offer treatment to your symptomatic floater patients with greater safety and efficacy than ever before.


Reflex Technology offers a number of advantages, including:

Full visualization from the cornea to the retina
Visualizing floaters and assessing their position relative to the lens or retina, has never been easier; True Coaxial Illumination provides a full view from the cornea to the retina along with much‐needed spatial context.

Treat with greater accuracy

Move effortlessly between on­‐axis and off‐axis viewing to visualize floaters in the anterior and posterior segments with greater accuracy than ever before.

Lower energy treatments

Higher-­power density and precisely controlled plasma formation ensures that fewer shots are required to effectively treat floaters.

MEET THE EXPERT SESSIONS, REFLEX™ TECHNOLOGY

ELLEX® EXHIBIT #C108

Stop by the Ellex® Exhibit #C108 to meet LFT experts Dr. Inder P. Singh and Dr. David Lubeck to discuss his treatment pearls and surgical tips for Reflex™ Technology in the treatment of debilitating floaters.

FACULTY

Inder P. Singh
MD (USA)
David Lubeck
MD (USA)

SATURDAY, 14 SEP
3:00pm – 4:00pm

SUNDAY, 15 SEP
3:00pm – 4:00pm

Register your interest

Note: this session is not hosted as part of the official program of the ESCRS 2019.

PHYSICIAN DINNER

Join your colleagues and leading experts Dr. Inder P. Singh and Dr. Andrzej Dmitriew for an intimate dinner discussion to address treatment pearls and surgical tips for Reflex™ Technology in the treatment of debilitating floaters. Prof John Marshall will address 2RT and how it stimulates a natural, biological healing response to slow the degenerative processes that cause retinal disease, including AMD.

FACULTY

Inder P. Singh
MD (USA)
Andrzej Dmitriew
MD (Poland)
John Marshall
PhD, FMedSci, FRCPath, FRCOphth (Hon) (UK)

DATE: Sunday, 15 September

TIME: 6:00PM - 10:00PM

VENUE: Les Turbulentes Restaurant
136 Rue de Lourmel
Paris, 75015

Register your interest

Note: this event is not affiliated with the official program of the ESCRS 2019.

“We have been programmed to minimize the impact of floaters on patients' daily lives because we had no viable solution. Today, we have a solution. “

INDER P. SINGH, MD (USA)

Ellex® is the manufacturer of Reflex™ Technology for use in the treatment of symptomatic floater patients. It has been approved for the indication of Posterior Membranectomy (incl. Nd:YAG Laser Vitreolysis/Laser Floater Treatment) whereby it may potentially improve the patient’s perception of visual functionality. Ellex® does not accept any responsibility for use of the system outside of these indications.

Ultra Q Reflex™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market release for the indications of Posterior Membranectomy (incl. Nd:YAG Laser Vitreolysis/Laser Floater Treatment), Capsulotomy and Laser Iridotomy.

“Visualize the entire vitreous – in perfect focus, from posterior lens to the retina.”

Visualize, diagnose and monitor pathology more accurately and more efficiently with the Eye Prime™ — a breakthrough in ultrasound technology that transforms your view of even the finest ocular structures.


Six-­Ring Phased Annular Array Technology

The Eye Prime™ features proprietary Six-­‐Ring Phased Annular Array Technology. Optimally configured for use in ophthalmology, this technology transmits and receives ultrasound waves from six concentric rings or transducers. This enables fine focus adjustment through a wide range of depths in 1mm increments – and thereby enables you to focus anywhere in the posterior segment and beyond.*
(*Available with 12MhZ and 18 MHz modes.)

Agile Focus™ for image optimization

Proprietary algorithms enable you to incrementally adjust focus within 1mm increments of the entire range of the operating depth, thereby enabling dynamic focus adjustment – and allowing you to see what has never been seen before.


“Clinically proven to delay progression to late-­stage AMD in selected patients.1*


Until now, therapies for Age-­Related Macular Degeneration (AMD) have only focused on late stage treatments that attempt to manage the symptoms experienced by patients — by which stage vision loss, and or damage has already occurred. 

In contrast, 2RT™ Retinal Rejuvenation Therapy provides ophthalmologists with the potential to intervene earlier in the disease process with the aim of slowing the degeneration process.

The multi-­center, double-­masked, randomized sham-controlled LEAD trial recently showed that 2RT™ Retinal Rejuvenation from Ellex® achieves a 77% reduction in the rate of progression to late-­stage AMD in selected patients, compared to sham non-­treated group.*


  • 2RT™ utilizes Nanopix™ Technology comprising solid‐state nanosecond laser technology and a pixelated beam profile.
  • 2RT™ induces a mononuclear cell response in the treatment of early AMD, including the stimulation of microglia.

1. Guymer RH, Wu Z, Hodgson LAB, et al. Sub‐Threshold Nanosecond Laser Intervention in Age­‐Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018.
*Post hoc analysis . Non‐RPD patients.

“… if we can slow down the basal rate of Bruch’s Membrane aging with 2RT™ and restore function to what it was when the patient was in their teens, we should be able to significantly delay AMD onset.”

PROF. JOHN MARSHALL PHD, FMEDSCI, FRCPATH, FRCOPHTH (HON) (UK)
FROST PROFESSOR OF OPHTHALMOLOGY, INSTITUTE OF OPHTHALMOLOGY, UNIVERSITY COLLEGE, MOORFIELDS EYE HOSPITAL, UK

Ellex® is the manufacturer of 2RT™. It has been approved for the indications Clinically Significant Macular Edema (CSME) and in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular appearance and function under CE marking. Ellex® does not accept any responsibility for use of the system outside of these indications.

2RT™ has a CE Mark (Conformité Européenne) for treatment in patients with early AMD where it can produce bilateral improvements in macular appearance and function.

2RT™ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) (510k) Market clearance for the treatment of Clinically Significant Macula Edema (CSME).

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More